The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.

COVID vaccine, AstraZeneca

A large study into rare blood clots linked with AstraZeneca’s COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side effects from the shot.

Moderna Inc. has begun a late-stage study of a vaccine for respiratory syncytial virus (RSV) based on the same technology used to develop the company’s COVID-19 shots.

The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”

U.S. health regulators are looking at authorizing a potential fourth dose of a COVID-19 vaccine in the fall, the Wall Street Journal reported on February 19, citing sources familiar with the matter.

Moderna Inc. said on February 18 the company is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.

At least one model from the University of Washington’s Institute for Health Metrics and Evaluation estimates that at this time, 73 percent of Americans are immune to Omicron, and it could rise to 80 percent by mid-March.

An Omicron-specific booster could be ready by August, the CEO of U.S. biotech firm Moderna told Reuters, but the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.

Delivery of Pfizer Inc. and BioNTech SE’s vaccine to combat the Omicron COVID-19 variant was delayed by several weeks due to a slower-than expected data gathering process, BionTech Chief Executive Ugur Sahin told Germany’s Bild.

BioNTech’s co-founder and top executive said the vaccine maker has no plans to enforce its intellectual property rights should organizations in Africa strike out on their own to produce unauthorized versions of the company’s shot.